| Product Unit Size | Cost | Quantity | Stock |
|---|
LY-3214996 is a selective inhibitor of ERK1/2. ERK1/2 inhibitors offer a targeted approach to cancers in which the RAS/MAPK signaling pathway is dysregulated. These compounds can be successful when Braf and MEK inhibitor efficacy is lost due to developed drug resistance. LY-3214996 has demonstrated potent antitumor effects in several human cancer xenograft models, including Braf or Kras mutant colorectal, lung, and pancreatic cancer models.
| Cas No. | 1951483-29-6 |
|---|---|
| Purity | ≥98% |
| Formula | C22H27N7O2S |
| Formula Wt. | 453.57 |
| Chemical Name | 6,6-dimethyl-2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5-(2-morpholin-4-ylethyl)thieno[2,3-c]pyrrol-4-one |
| IUPAC Name | 6,6-Dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]-4-pyrimidinyl}-5-[2-(4-morpholinyl)ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one |
| Synonym | LY 3214996, LY3214996 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Gaiying Z., McMillen W., et al. Identifying high quality, potent and selective pyrimidinylthienopyrrolone inhibitors of ERK1/2 kinase: LY3214996. Cancer Res. 77(13 Suppl.):3231 (2017).